CompletedNot Applicable

Neuroprotective Efficacy of Postnatal Magnesium Sulphate in Term Infants With Birth Asphyxia

Pakistan178 participantsStarted 2023-03-24

Plain-language summary

Birth/Perinatal asphyxia in Pakistan continues to be a leading cause of neonatal mortality and morbidity. It is estimated that around 80 to 120,000 neonates either suffer from or die from birth/perinatal asphyxia every year. In addition to the large number of deaths a larger number of babies who survive suffer from neuro-developmental disorders adding to the health burden to the society and the nation. To date other than prevention (which requires global efforts to improve maternal education and health care) the therapies available to treat infants who have suffered from birth asphyxia have been either technically too complex or extremely expensive.

Who can participate

Age range1 Hour – 24 Hours

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Term and near term infants (≥35 weeks gestation) with moderate to severe birth asphyxia Age at admission \< 24 hours Exclusion Criteria: * Babies who could not be given first injection before 24 hours of age Infants with major congenital malformations, sepsis, congenital heart defects, Intracranial hemorrhage and surgical problems Babies received intubated in emergency Babies receiving therapeutic hypothermia Infants with disorders of metabolism Infants in whom cause other than asphyxia is established as the reason for not initiating or sustaining breathing at birth.

What they're measuring

number of participants died (receiving mgso4)

Timeframe: 6 hours

number of participants diednumber (difference in time of administration)

Timeframe: 24 hours

Trial details

NCT IDNCT05707962

SponsorUniversity of Health Sciences Lahore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-24